Pfizer Asks SCOTUS to Narrow Enforcement of Anti-Kickback Statute

In an analysis for Law360, Jeff Overley describes Pfizer's efforts to persuade the Supreme Court that the Anti-Kickback Statute suffers from “staggeringly overbroad” enforcement with “nearly limitless” reach, ensnaring “a wide swath of routine, beneficial conduct.” The pharmaceutical company argues that the statute should only apply in situations where the funds are offered with intent to corrupt the recipient's decision-making.